TY  - GEN
T1  - DMSO reduces the cytotoxicity of anticancer ruthenium complex KP1019 in yeast
AU  - Davis, Jonathan
AU  - Cetto, Anne
AU  - Campbell, Mary
AU  - Scoggins, Seth
AU  - Stultz, Laura
AU  - Hanson, Pamela
DO  - 10.17912/micropub.biology.000436
UR  - http://beta.micropublication.org/journals/biology/micropub-biology-000436/
AB  - In an early stage dose-escalation clinical trial, anticancer ruthenium complex indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (also known as KP1019), stabilized disease progression in five of six evaluable patients (Hartinger et al. 2008). However, KP1019’s low solubility prevented identification of the maximum tolerated dose. In laboratory studies, the challenge of KP1019’s poor solubility is often overcome by dissolving the drug in dimethyl sulfoxide (DMSO) before diluting it into the growth medium or buffer being used in a particular assay (Bergamo et al. 2009; Singh et al. 2014; Golla et al. 2017; Śpiewak et al. 2019). Though many studies control for the biological impacts of DMSO itself by including a vehicle only control, the impacts of DMSO on KP1019’s chemistry and bioactivity have not been directly tested. Notably, a previous study showed that the activities of the platinum drugs cisplatin and carboplatin are reduced by 87 to 98% respectively when solubilized with DMSO (Hall et al. 2014). Given this finding and ruthenium’s high affinity for sulfur containing ligands, we hypothesized that DMSO would also affect KP1019.
PY  - 2021
JO  - microPublication Biology
ER  -